
Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. We are creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.

HZT-501: Positive Phase 3 Data
The two pivotal trials are complete and have met their primary endpoints
06.29.09
Horizon Therapeutics Names Dr. Jeffery W. Sherman Executive Vice President and Chief Medical Officer
12.02.08
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints